Advances in peptide pharmaceuticals

Current Pharmaceutical Biotechnology

Volumn 10, Issue 1, 2009, Pages 122-137

  Stevenson, Cynthia L ^a  

^a Independent Pharmaceuticals Consultant   (United States)

Author keywords

Drug delivery; Peptide; Peptidomimetic

Indexed keywords

ALBIGLUTIDE; ATRIGEL; BORTEZOMIB; CALCITONIN; CILENGITIDE; CJC 1131; CJC 1134; EPTIFIBATIDE; EXENDIN 4; GATTEX; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GONADORELIN AGONIST; GOSERELIN; HISTRELIN; INSULIN; LEPTIN; LEUPROLIDE ACETATE INJECTION; LEUPRORELIN; LIRAGLUTIDE; METFORMIN; MICALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-31][27 LEUCINE] AMIDE 22,26 AMIDE; PARATHYROID HORMONE[1-34]; PEPTIDE DERIVATIVE; PEPTIDE YY; PEPTIDE YY [3-36]; PRAMLINTIDE; RECOMBINANT PARATHYROID HORMONE; SALCATONIN; SULFONYLUREA; SUPPRESLIN LA; TEDUGLUTIDE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; CLINICAL TRIAL; CROHN DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG HALF LIFE; DRUG INACTIVATION; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HUMAN; HYPERCALCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; REVIEW; SHORT BOWEL SYNDROME;

ANIMALS; BIOLOGICAL PRODUCTS; HUMANS; MOLECULAR MIMICRY; PEPTIDES; TECHNOLOGY, PHARMACEUTICAL;

EID: 65949101647     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920109787048634     Document Type: Review

References (141)

1. Pharmaceutical Industry Profile (2008) Pharmaceutical Research and Manufacturers of America, Washington DC.
2. American Council of Clinical Endocrinologists. (2005) State of diabetes in america: striving for better control, http:/ /www.aace.com/ public/awareness/ stateofdiabetes/DiabetesAmericaReport.pdf
3. Physicians Desk Reference, 60th ed. (2006) Montvale, NJ: Thomson Publishing.
4. Dungan, K. and Buse, J.B. (2005) Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin. Diabetes, 23, 56-62.
5. Chang, X.; Keller, D.; Bjorn, S. and Led, S.S. (2001) Structure and folding of glucagon-like peptide-1-(7-36)-amide in aqueous trifluoroethanol studied by NMR spectroscopy. Magn. Reson. Chem., 39, 477-483.
6. Meier, J.J.; Gallwitcz, B. and Nauck, M.A. (2003) Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs, 17, 93-102.
7. Deacon, C.F.; Johnsen, A.H. and Holst, J.J. (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab., 80, 952-957.
8. Nauck, M.A. (1997) Glucagon like peptide 1. Curr. Opin. Endocrinol. Diabetes, 4, 291-299.
9. Green, B.D.; Irwin, N.; Gault; V.A.; O'Hart, F.P.M. and Flatt, P.R. (2005) Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Br. J. Diabetes Vasc. Dis., 5, 134-140.
10. www.amylin.com/pipeline
11. Knudsen, L.B. (2004) Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes. J. Med. Chem., 47, 4128-4134.
12. Leger, R.; Thibaudeau, K.; Robitaille, M.; Quraishi, O.; van Wyk. P.; Bousquet-Gagnon, N.; Carette, J.; Castaigne, J.P. and Bridon, D.P. (2004) Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1 (7-36) analog. Bioorg. Med. Chem. Lett., 14, 4395-4398.
13. Giannoukakis, N. (2003) CJC-1131. ConjuChem. Curr. Opin. Invest. Drugs, 4, 1245-1249.
14. Thorkildsen, C.; Neve, S.; Larsen, B.D.; Meier, E. and Petersen, J.S. (2003) Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J. Pharmacol. Exp. Ther., 307, 490-496.
15. Ahren, B. and Schmitz, O. (2004) GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm. Metab. Res., 36, 867-876.
16. Holst, J.J. (2005) Glucagon-like peptide-1: physiology and therapeutic potential. Curr. Opin. Endocrinol. Diabetes, 12, 56-62.
17. www.roche.com
18. www.intarcia.com
19. McQueen, J. (2005) Pramlintide acetate. Am. J. Health Syst. Pharm., 62, 2363-72.
20. Ryan, G.J.; Jobe, L.J. and Martin, R. (2005) Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin. Ther., 27, 1500-1512.
21. Kruger, D.F. and Gloster, M.A. (2004) Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs, 64, 1419-1432
22. Small, C.J. and Bloom, S.R. (2005) The therapeutic potential of gut hormone peptide YY3-32 in the treatment of obesity. Expert Opin. Investig. Drugs, 14, 647-653.
23. Joshi, A.B.; Sawai, M.; Kearney, W.R. and Kirsch, L.E. (2005) Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon. J. Pharm. Sci., 94, 1912-1927.
24. www.diobex.com
25. www.npsp.com/news_releasetxt
26. Burrin, D.G.; Petersen, Y.; Stoll, B. and Sangild, P. (2001) Glucagon like peptide 2: A nutrient responsive gut growth factor. J. Nutr., 131, 709-712.
27. Petersen, Y.M.; Thorkildsen, C.; Petersen, J.S. and Kjolbye, A.L. (2007) ZP1846. A novel therapeutic candidate for the treatment of chemotherapy induced diarrhea. Mult. Assoc. Suppor. Care Cancer, September 27, 2007, Poster #192.
28. Travis, S.; Yap, L.M.; Hawkey, C.; Warren, B.; Path, F.R.C.; Lazarov, M.; Fong, T. and Tesi, R.J. (2005) RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis., 11, 713-719.
29. www.sapphirethera.com
30. Raun, K.; Hansen, B.S.; Johansen, N.L.; Thorgersen, H.; Madsen, K.; Andersen, M. and Andersen, P.H. (1998) Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol., 139, 552-561.
31. World Health Organization. (1994) WHO Technical Report Series 843, WHO, Geneva, Switzerland.
32. Morley, P.; Whitfield, J.F. and Willick, G.E. (2001) Parathyroid hormone: An anabolic treatment for osteoporosis. Curr. Pharm. Des., 7, 671-687.
33. Morley, P. (2005) Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin. Drug Deliv., 2, 993-1002.
34. Shea, J.E. and Miller, S.C. (2005) Skeletal function and structure: implications for tissue targeted therapeutics. Adv. Drug Deliv. Rev., 57, 945-957.
35. Motta, A.; Andreotti, G.; Amodea, P.; Strazzullo, G. and Morelli, M.A.C. (1998) Solution structure of human calcitonin in membrane-mimetic environment: the role of the amphipathic helix. Proteins Struct. Funct. Genet., 32, 314-323.
36. Siligardi, G.; Samor, B.; Melandr, S.; Visconti, M. and Drake, A.F. (1994) Correlations between biological activities and conformational properties for human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD spectroscopy. Eur. J. Biochem., 221, 1117-1125.
37. Hirabayashi, H. and Fujisaki, J. (2003) Bone specific drug delivery systems: approaches via chemical modification of bone seeking agents. Clin. Pharmacokinet., 41, 1319-1330.
38. Fogelman, I. and Cool, G.J. (1999) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, (Favus, M.J., Ed.), Lippincott Williams & Wilkins, Philadelphia, pp. 146-152.
39. BioWorld Today, Monday Oct 2, 2006, p. 5.
40. Lu, R.H.; Kopeckova, P. and Kopecek, J. (1999) Degradation and aggregation of human calcitonin in vitro. Pharm. Res., 16, 359-367.
41. Baudys, M.; Mix, D. and Kim, S.W. (1996) Stabilization and intestinal absorption of human calcitonin. J. Control. Release, 39, 145-151.
42. Milstein, S.J.; Leipold, H.; Sarubbi, D.; Leone-Bay, A.; Mlynek, G.M.; Robinson, J.R.; Kasimova, M. and Freire, E. (1998) Partially unfolded proteins efficiently penetrated cell membranes-implication for oral drug delivery. J. Control. Release, 53, 259-267.
43. Buclin, T.; Rochat, M.C.; Burkhardt, P.; Azria, M. and Attinger, M. (2002) Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J. Bone Miner. Res., 17, 1478-1485.
44. Tanko, L.B.; Bagger, Y.Z.; Alexandersen, P.; Devogelaer, J.P.; Reginster, J.Y.; Chick, R.; Olson, M.; Benmammar, H.; Mindeholm, L.; Azria, M. and Christiansen, C. (2004) Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J. Bone Miner. Res., 19, 1531-1538.
45. Hodsman, A.B.; Hanley, D.A.; Ettinger, M.P.; Bolognese, M.A.; Fox, J.; Metcalfe, A.J. and Lindsay, R. (2003) Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab., 88, 5212-5220.
46. Stoll, B.R.; Leipold, H.R.; Milstein, S. and Edward, D.A. (2000) A mechanistic analysis of carrier mediated oral delivery of protein therapeutics. J. Control. Release, 64, 217-228.
47. www.bone-ltd.com
48. Marx, U.C.; Austermann, S.; Mayer, P.; Adermann, K.; Ejchart, A.; Sticht, H.;Walter, S.; Schmid, F.X.; Jaenike, R.; Forssmann, W.G. and Rosch, P. (1995) Structure of human parathyroid hormone 1-37 in solution. J. Biol. Chem., 270, 15194-15202.
49. Barden, J.A. and Kemp, B.E. (1993) NMR solution structure of human parathyroid hormone (1-34). Biochemistry, 32, 7126-7132.
50. Dobnig, H. and Turner, R.T. (1997) The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology, 138, 4607-4612.
51. Lotinun, S.; Sibonga, J.D. and Turner, R.T. (2002) Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine, 17, 29-36.
52. Lane, N.; Sanchez, S.; Benant, H.; Modin, G.; Pierini, E. and Arnaud, C. (2000) Short term increases in bone turnover markers predict parathyroid hormone induced spinal bone mineral density gains in menopausal women with glucocorticoid osteoporosis. Osteoporos. Int., 11, 434-442.
53. Cosman, F.; Nieves, J.; Woeflert, I.; Formica, C.; Gordon, S.; Shen, V. and Lindsay, R. (1998) Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J. Bone Miner. Res., 13, 1051-1055.
54. Schwietert, H.R.; Groen, E.W.; Sollie, F.A. and Jonkman, J.H. (1997) Singe dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH (1-84)] in healthy postmenopausal volunteers. Clin. Pharmacol. Ther., 61, 360-376.
55. 2 and hPTH (1-34) in healthy humans. J. Clin. Endocrinol. Metab., 84, 2739-2743.
56. www.zelostherapeutics.com
57. Pfutzner, A.; Flacke, F.; Pohl, R.; Linkie, D.; Engelbach, M.; Woods, R.; Forst, T.; Beyer, J. and Steiner, S.S. (2003) Pilot study with Technosphere/PTH (1-34) - a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Horm. Metab. Res., 35, 319-323.
58. Wilson, B.W.; Grant, M.L.; Steiner, S.S. and Pohl, R. (1999) Technospheres for pulmonary and nasal applications. Exp. Clin. Endocrinol. Diabetes, 2002, 545-548.
59. www.alkermes.com
60. Vanbever, R.; Mintzes, J.D.; Wang, J.; Nice, J.; Chen, D.; Batycky, R.; Langer, R. and Edwards, D.A. (1999) Formulation and physical characterization of large porous particles for inhalation. Pharm. Res., 16, 1735-1742.
61. Codrons, V.; Vanderbist, F.; Ucakar, B.; Preat, V. and Vanbever, R. (2004) Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci., 93, 1241-1252.
62. Codrons, V.; Vanderbist, F.; Verbeek, R.K.; Arras, M.; Lison, D.; Preat, V. and Vanbever, R. (2003) Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci., 92, 938-950.
63. www.nastech.com
64. Nastech's Parathyroid Hormone (PTH1-34) Nasal Spray Demonstrated Similar Exposure Levels To Approved Injectable Product In Phase I Study In The Elderly. Medical News Today, 27 June 2006.
65. Agu, R.U.; Valivet, S.; Earles, D.C.; Klausner, M.; Hayden, P.J.; Wermeling, D.P. and Stinchocomb, A.L. (2004) Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)] teriparatide in rats. Endocr. Res., 30, 455-467.
66. Johnson, P.H. and Quay, S.C. (2005) Advances in nasal drug delivery through tight junction technology. Expert Opin. Drug Deliv., 2, 281-298.
67. Chen, S.C.; Eiting, K.; Cui, K.; Leonard, A.K.; Morris, D.; Li, C.Y.; Farber, K.; Sileno, A.P.; Houston, M.E.; Johnson, P.H.; Quay, S.C. and Constantino, H.R. (2006) Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J. Pharm. Sci., 95, 1364-1371.
68. Matsumoto, T.; Shiraki, M.; Nakamura, T.; Hagino, H. and Inuma, H. (2004) Daily nasal spray of hPTH (1034) for 3 months increases bone mass in osteoporotic patients. J. Bone Miner. Res., 19, S44.
69. Leone-Bay, A.; Sato, M.; Paton, D.; Hunt, A.H.; Sarubbi, D.; Carozza, M.; Chou, J.; McDonough, J. and Baughman, R.A. (2001) Oral delivery of biologically active parathyroid hormone. Pharm. Res., 18, 964-970.
70. Werle, M.; Samhaber, A. and Bernkop-Schnurch, A. (2006) Degradation of teriparatide by gasto-intestinal proteolytic enzymes. J. Drug Target., 14, 109-115.
71. Mehta, N.; Stern, W.; Sturmer, A.; Bolat, B.; Chen, J. and Gillgan, J. (2001) Oral delivery of PTH analogs by a solid dosage formulation. J. Bone Miner. Res., 16, S540.
72. Levin, G. (2008) Advances in radio-frequency transdermal drug delivery. Pharm. Technol., 32, 12-19.
73. www.transpharma.com
74. Prausnitz, M.R. (2004) Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev., 56, 581-587.
75. Aartanto, W.; Davis, S.P.; Holiday, N.R.; Wang, J.; Gill, H.S. and Prausnitz, M.R. (2004) Transdermal delivery of insulin using microneedles in vivo. Pharm. Res., 21, 947-952.
76. Gopalakrishnan, B.; Hwang, S. and Loughrey, H. (2004) Administration of ThPTH to humans using Macroflux transdermal technology results in rapid delivery of biologically active PTH. J. Bone Miner. Res., 19, S460.
77. www.alteatherapeutics.com
78. www.acologix.com
79. www.orthologic.com
80. Parkan, D.M.; Bray, F.; Felay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA Cancer J. Clin., 55, 74-108.
81. Wright, J.C.; Leonard, S.T.; Stevenson, C.L.; Beck, J.M.; Chen, G.; Jao, R.M.; Johnson, P.A.; Leonard, J. and Skowronski, R.J. (2001) An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Control. Release, 75, 1-10.
82. Adjei, A.J. and Hsu, L. (1993) Leuprolide and other LHRH analogues in Stability and Characterization of Protein and Peptide Drugs, (Wang, Y.J. and Pearlman, R., Eds.), Plenum Press, New York, 159-199.
83. Nikiforovich, G.V. and Marshall, G.R. (1993) Conformation function relationships in LHRH analogs II. Conformations of LHRH peptide agonists and antagonists. Int. J. Pept. Protein Res., 42, 181-193.
84. Bonvini, P.; Zorzi, E.; Basso, G. and Rosolen, A. (2007) Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia, 21, 838-42.
85. www.medicalnewstoday.com/articles/42498.php
86. Butts, C.; Maksymiuk, A.; Glenwood, G.; Soulieres, D.; Erie, M.; Cormier, Y.; Ellis, P.M.; Price, A.; Ravinder, S. and Nevin, M. (2007) A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP 25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. J. Thoracic Oncol., 2, 5332-5333.
87. www.pipelinereview.com/content/view/11590/100/
88. Friess, H,; Langrehr, J.M.; Oettle, H.; Raedle, J.; Niedergethmann, M.; Dittrich, C.; Hossfeld, D.K.; Stoger, H.; Neyns, B.; Herzog, P.; Piedbois, P.; Dobrowolski, F.; Scheithauer, W.; Hawkins, R.; Katz, F.; Balcke, P.; Vermorken, J.; van Belle, S.; Davison, N.; Abad Esteve, A.; Sastellano, D.; Kleeff, J.; Tempia-Caliera, A.A.; Kovar, A. and Nippgen, J. (2006) A randomized multi-center phase II trial of angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreactic cancer. BMC Cancer, 6, 285-296.
89. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn. U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.R.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.D.; Eisenhaur, E. and Mirimanoff, R.O. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352, 987-996.
90. www.clinuvel.com
91. 7-α-MSH (Melanotan-I) on tanning: a dose-ranging study. J. Dermatol. Treat., 10, 127-132.
92. Keating, G.M. and Goa, K.L. (2003) Nesiritide: A review of its use in acute decompensated heart failure. Drugs, 63, 47-50.
93. Rosenkranz, B.; Bork, K.; Frank, J.; Kreuz, W.; Dong, L. and Knolle, J. (2005) Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema. Clin. Pharmacol. Ther., 77, P14.
94. www.jerini.com
95. Haugan, K. and Petersen, J.S. (2007) Gap junction modifying antiarrhythmic peptides: therapeutic potential in atrial fibrillation. Drugs Future, 32, 245-260.
96. www.affymax.com
97. www.aplagen.com
98. Loosli, H.R.; Kessler, H.; Oschkinat, H.; Weber, H.P.; Petcher, T.J. and Widmer, A. (1985) The conformation of cyclosporin A in the crystal and in solution. Helv. Chim. Acta, 68, 682-704.
99. 6 by a combination of homo and heteronuclear two-dimensional techniques. Helv. Chim. Acta, 68, 661-681.
100. Ko SY, Dalvit C. (1992) Conformation of cyclosporin A in polar solvents. Int. J. Peptide Protein Res., 40, 380-382.
101. Verheyden, P.; Jaspers, H.; Wolf, E. and Van Binst, G. (1994) Conformational study of cyclosporin A in acetone at low temperature. Int. J. Peptide Protein Res., 44, 364-371.
102. Weber, C.; Wider, G.; von Freyberg, B.; Traber, R.; Braun, W.; Widmer, H. and Wuthrich, K. (1991) The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. Biochemistry, 30, 6563-6574.
103. Wenger, R.M.; Francq, J.; Bowermann, G.; Walliser, L.; Widman, A. and Widmer, H. (1994) The 3D structure of cyclosporin analog in water is nearly identical to the cyclophilin bound cyclosporin conformation. FEBS Lett., 340, 255-259.
104. Wuthrich, K.; von Freyberg, B.; Weber, C.; Wider, G.; Traver, R.; Widmer, H. and Braun, W. (1991) Receptor-induced conformation change of the immunosuppressant cyclosporin A. Science, 254, 953-954.
105. Merck Index. (2006) Whitehouse Station, 14th ed., NJ: Merck & Co, Inc.
106. Warren, K.G.; Catz, I.; Ferenczi, L.Z. and Krantz, M.J. (2006) Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohorts of patients with progressive multiple sclerosis: Results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol., 13, 887-895.
107. www.peptimmune.com
108. Vandenbark, A.A.; Culbertson, N.E.; Bartholomew, R.M.; Huan, J.; Agotsch, M.; LaTocha, D.; Yadav, V.; Mass, M.; Whitham, R.; Lovera, J.; Milano, J.; Theofan, G.; Chou, Y.K.; Offner, H. and Bourdette, D.N. (2008) Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology, 123, 66-78.
109. Burge, D.J.; Shu, C. and Martin, R.W. (2006) TRU-015, a small modular immunopharmaceutical (SMIP™) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. American College of Rheumatology 70th Annual Meeting, November 11-15, 2006, Washington, DC. Presentation 463/463.
110. www.tercica.com
111. Melacini, G.; Zhu, Q. and Goodman, M. (1997) Multiconformational NMR analysis of sandostain (Octreotide): Equilibrium between β-sheet and partially helical structures. Biochemistry, 36, 1233-1241.
112. www.novartisoncology.us
113. www.ambrilia.com
114. Sawyer, W.H. and Manning, M. (1988) Synthetic analogs of vasopressin. ISI Atlas Sci., 2, 252-256.
115. Richardson, D.W. and Robinson, A.G. (1985) Desmopressin. Ann. Intern. Med., 103, 228-239.
116. He, H.T.; Gursoy, N.; Kupczyk-Subotkowska, L.; Tian, J.; Williams, T. and Siahaan, T.J. (2006) Synthesis and chemical stability of a disulfide bond in a model cyclic pentapeptide: cyclo (1,4)-Cys-Gly-Phe-Cys-Gly-OH. J. Pharm. Sci., 95, 2222-2234.
117. Basus, V.J.; Nadasdi, L.; Ramachandran, J. and Miljanich, G.P. (1995) Solution structure of ω-conotoxin MVIIA using 2D NMR spectroscopy. FEBS Lett., 370, 163-169.
118. Montgomery, S.A.; Feighner, J.P.; Sverdlov, L.; Srivastava, R.K.; Cunningham, L.A.; Kiev, A.; Hlavka, J. and Tonelli, G. (2005) Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. Int. J. Neuropsychopharm., 9, 517-528.
119. Patocka, J.; Slaninova, J. and Kunesova, G. (2005) Neuroprotective peptides as drug candidates against Alzheimer's disease. J. Appl. Biomed., 3, 1-7.
120. Sieber, S.A. and Marahiel, M.A. (2003) Learning form natures drug factories: Nonribosomal synthesis of macrocyclic peptides. J. Bacteriol., 185, 7036-7043.
121. Hancock, R.E.W. and Chapple, D.S. (1999) Peptide antibiotics. Antimicrob. Agents Chemother., 43, 1317-1323.
122. Dvorchik, B.H.; Brazier, D.; DeBruin, M.F. and Arbeit, R.D. (2003) Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother., 47, 1318-1323.
123. www.xoma.com
124. Jenssen, H.; Hamill, P. and Hancock, R.E.W. (2006) Peptide Antimicrobial Agents. Clin. Microbiol. Rev., 19, 491-511.
125. www.genaera.com
126. www.cadencepharm.com
127. Hancock, R.E.W. and Sahl, H.G. (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol., 24, 1551-1557.
128. Denning, D. (2003) Echinocandin antifungal Drugs. Lancet, 362, 1142-1151.
129. Raasch, R.H. (2004) Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev. Anti-infect. Ther., 2, 499-508.
130. Li, C.; Fleisher, D.; Li, L.; Schwier, J.R.; Sweetana, S.A.; Vasudevan, V.; Zornes, L.L.; Pao, L.H.; Zhou, S.Y. and Stratford, R.E. (2001) Regional dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. J. Pharm. Sci., 90, 47-57.
131. Tsai, H.Y.; Ray, P.A. and Bobeck, L.A. (1996) Candiacidal activity of recombinant human salivary histatins-5 and variants. Infect. Immun., 64, 500-5007.
132. www.pacgenbiopharm.com
133. www.am-pharma.com
134. www.novabiotics.co.uk
135. Veiga, S.; Henriques, S.; Santos, N.C. and Castanho, C. (2004) Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem. J., 377, 107-110.
136. www.sciclone.com
137. www.amunix.com
138. www.aileronrx.com
139. Walensky, L.D.; Kung, A.L.; Escher, I.; Malia, T.H.; Barbuto, S.; Wright, R.D.; Wagner, G.; Verdine, G.L. and Korsmeye, S.J. (2004) Activation of apoptosis in vivo by a hydrocarbon stapled BH3 helix. Science, 305, 1466-1470.
140. www.peptx.com
141. Dings, R.P.M.; Arroyo, M.M.; Lockwood, N.A.; van Eijk, L.E.; Haseman, J.R.; Griffioen, A.W. and Mayo, K.H. (2003) β-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem. J., 373, 281-288.